Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

References

1. 1.↵
   2. King KG,
   3. Kositwattanarerk A,
   4. Genden E, et al

   . Cancers of the oral cavity and oropharynx: FDG PET with contrast-enhanced CT in the posttreatment setting. Radiographics 2011;31:355–73 doi:10.1148/rg.312095765 pmid:21415184

   CrossRefPubMed
2. 2.↵
   2. Tantiwongkosi B,
   3. Yu F,
   4. Kanard A, et al

   . Role of (18)F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma. World J Radiol 2014;6:177–91 doi:10.4329/wjr.v6.i5.177 pmid:24876922

   CrossRefPubMed
3. 3.↵
   2. Cheung PK,
   3. Chin RY,
   4. Eslick GD

   . Detecting residual/recurrent head neck squamous cell carcinomas using PET or PET/CT: systematic review and meta-analysis. Otolaryngol Head Neck Surg 2016;154:421–32 doi:10.1177/0194599815621742 pmid:26715675

   CrossRefPubMed
4. 4.↵
   2. Sagardoy T,
   3. Fernandez P,
   4. Ghafouri A, et al

   . Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up. Head Neck 2016;38(Suppl 1):E1271–76 doi:10.1002/hed.24204 pmid:26315809

   CrossRefPubMed
5. 5.↵
   2. Sheikhbahaei S,
   3. Taghipour M,
   4. Ahmad R, et al

   . Diagnostic accuracy of follow-up FDG PET or PET/CT in patients with head and neck cancer after definitive treatment: a systematic review and meta-analysis. AJR Am J Roentgenol 2015;205:629–39 doi:10.2214/AJR.14.14166 pmid:26295652

   CrossRefPubMed
6. 6.↵
   2. Chen SW,
   3. Hsieh TC,
   4. Yen KY, et al

   . Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer. Laryngoscope 2014;124:2732–38 doi:10.1002/lary.24826 pmid:25042474

   CrossRefPubMed
7. 7.↵
   2. Koshkareva Y,
   3. Branstetter BF 4th.,
   4. Gaughan JP, et al

   . Predictive accuracy of first post-treatment PET/CT in HPV-related oropharyngeal squamous cell carcinoma. Laryngoscope 2014;124:1843–47 doi:10.1002/lary.24617 pmid:24474646

   CrossRefPubMed
8. 8.↵
   2. Ho AS,
   3. Tsao GJ,
   4. Chen FW, et al

   . Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer 2013;119:1349–56 doi:10.1002/cncr.27892 pmid:23225544

   CrossRefPubMed
9. 9.↵
   2. Meerwein CM,
   3. Queiroz M,
   4. Kollias S, et al

   . Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. Swiss Med Wkly 2015;145:w14116 doi:10.4414/smw.2015.14116 pmid:25701645

   CrossRefPubMed
10. 10.↵
    2. McDermott M,
    3. Hughes M,
    4. Rath T, et al

    . Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer. AJNR Am J Neuroradiol 2013;34:1632–36 doi:10.3174/ajnr.A3494 pmid:23639557

    Abstract/FREE Full Text
11. 11.↵
    2. Mehanna H,
    3. Wong WL,
    4. McConkey CC, et al

    ; PET-NECK Trial Management Group. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med 2016;374:1444–54 doi:10.1056/NEJMoa1514493 pmid:27007578

    CrossRefPubMed
12. 12.↵
    2. Chen YJ,
    3. Rath T,
    4. Mohan S

    . PET-computed tomography in head and neck cancer: current evidence and future directions. Magn Reson Imaging Clin N Am 2018;26:37–49 doi:10.1016/j.mric.2017.08.003 pmid:29128005

    CrossRefPubMed
13. 13.↵
    2. Nayak JV,
    3. Walvekar RR,
    4. Andrade RS, et al

    . Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 2007;117:2129–34 doi:10.1097/MLG.0b013e318149e6bc pmid:17921898

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Porceddu SV,
    3. Pryor DI,
    4. Burmeister E, et al

    . Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011;33:1675–82 doi:10.1002/hed.21655 pmid:22076976

    CrossRefPubMed
15. 15.↵
    2. Brizel DM,
    3. Prosnitz RG,
    4. Hunter S, et al

    . Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;58:1418–23 doi:10.1016/j.ijrobp.2003.09.004 pmid:15050318

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Aiken AH,
    3. Farley A,
    4. Baugnon KL, et al

    . Implementation of a novel surveillance template for head and neck cancer: neck imaging reporting and data system (NI-RADS). J Am Coll Radiol 2016;13:743–46 doi:10.1016/j.jacr.2015.09.032 pmid:26577876

    CrossRefPubMed
17. 17.↵
    2. Krieger DA,
    3. Hudgins PA,
    4. Nayak GK, et al

    . Initial performance of NI-RADS to predict residual or recurrent head and neck squamous cell carcinoma. AJNR Am J Neuroradiol 2017;38:1193–99 doi:10.3174/ajnr.A5157 pmid:28364010

    Abstract/FREE Full Text
18. 18.↵
    2. Aiken AH,
    3. Hudgins PA

    . Neck imaging reporting and data system. Magn Reson Imaging Clin N Am 2018;26:51–62 doi:10.1016/j.mric.2017.08.004 pmid:29128006

    CrossRefPubMed
19. 19.↵
    2. Edge SB,
    3. Byrd DR,
    4. Compton CC, et al

    . AJCC cancer staging manual. 7th ed. New York: Springer; 2010:21–100
20. 20.↵
    2. Leung AS,
    3. Rath TJ,
    4. Hughes MA, et al

    . Optimal timing of first posttreatment FDG PET/CT in head and neck squamous cell carcinoma. Head Neck 2016;38(Suppl 1):E853–58 doi:10.1002/hed.24112 pmid:25917499

    CrossRefPubMed
21. 21.↵
    2. Newcombe RG

    . Statistical applications in orthodontics, Part II: confidence intervals for proportions and their differences. J Orthod 2000;27:339–40 doi:10.1093/ortho/27.4.339 pmid:11099576

    FREE Full Text
22. 22.↵
    2. Adelstein D,
    3. Gillison ML,
    4. Pfister DG, et al

    . NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw 2017;15:761–70 doi:10.6004/jnccn.2017.0101 pmid:28596256

    Abstract/FREE Full Text
23. 23.↵
    2. Sjövall J,
    3. Chua B,
    4. Pryor D, et al

    . Long-term results of positron emission tomography-directed management of the neck in node-positive head and neck cancer after organ preservation therapy. Oral Oncol 2015;51:260–66 doi:10.1016/j.oraloncology.2014.12.009 pmid:25553622

    CrossRefPubMed
24. 24.↵
    2. Bird T,
    3. Barrington S,
    4. Thavaraj S, et al

    . (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2016;43:1239–47 doi:10.1007/s00259-015-3290-4 pmid:26707387

    CrossRefPubMed
25. 25.↵
    2. Amin AB,
    3. Edge SB,
    4. Greene FL, et al

    . AJCC cancer staging manual. 8th ed. New York:Springer;2017:55–184
26. 26.↵
    2. de Langen AJ,
    3. Vincent A,
    4. Velasquez LM, et al

    . Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med 2012;53:701–08 doi:10.2967/jnumed.111.095299 pmid:22496583

    Abstract/FREE Full Text